Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SYRE 
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $53.9
1 Year Target Price $53.9
| 10 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.3% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 895.14M USD | Price to earnings Ratio - | 1Y Target Price 53.9 |
Price to earnings Ratio - | 1Y Target Price 53.9 | ||
Volume (30-day avg) 11 | Beta 2.88 | 52 Weeks Range 10.91 - 40.26 | Updated Date 09/17/2025 |
52 Weeks Range 10.91 - 40.26 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.48% | Return on Equity (TTM) -49.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 740792227 | Price to Sales(TTM) 650.22 |
Enterprise Value 740792227 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 60401000 | Shares Floating 46735243 |
Shares Outstanding 60401000 | Shares Floating 46735243 | ||
Percent Insiders 8.71 | Percent Institutions 106.92 |
Upturn AI SWOT
Spyre Therapeutics Inc.
Company Overview
History and Background
Spyre Therapeutics, Inc. was founded in 2022. It is a clinical-stage biotechnology company focused on developing new medicines to treat inflammatory bowel disease (IBD).
Core Business Areas
- Drug Development: Spyre focuses on developing novel antibody therapeutics for IBD, including ulcerative colitis and Crohn's disease.
Leadership and Structure
The leadership team includes key executives with experience in drug development and biotechnology. The company is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- SPY001: SPY001 is an anti-TL1A antibody. Clinical trials are underway. Competitors include Prometheus Biosciences (acquired by Merck), Roivant Sciences, and other companies developing anti-TL1A therapies.
- SPY002: SPY002 is an anti-alpha 4 beta 7 antibody. Clinical trials are underway. Competitors include Takeda (Entyvio), and other companies developing anti-alpha 4 beta 7 therapies.
Market Dynamics
Industry Overview
The IBD therapeutics market is a significant and growing market due to the increasing prevalence of IBD and the need for more effective treatments.
Positioning
Spyre Therapeutics is positioning itself as an innovative company in the IBD space, developing novel antibody therapeutics with potentially improved efficacy and safety profiles.
Total Addressable Market (TAM)
The IBD therapeutics market is projected to reach billions of dollars. Spyre aims to capture a share of this market with its pipeline of novel therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early stage company
- Limited financial resources compared to larger competitors
- Clinical trial risks
Opportunities
- Potential for breakthrough therapies in IBD
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- TAK
- MRK
- BMY
- ROIV
Competitive Landscape
Spyre Therapeutics faces competition from established pharmaceutical companies and other biotech companies developing IBD therapies. Its advantage lies in its novel therapeutic approaches, but it must overcome clinical trial risks and regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D investment and pipeline development.
Future Projections: Future growth depends on the success of clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead drug candidates and expanding the pipeline through research and development.
Summary
Spyre Therapeutics is an early-stage biotech company with a promising pipeline of IBD therapies. Its success depends on the positive results of its clinical trials. Competition in the IBD market is fierce, and the company must navigate regulatory hurdles to bring its therapies to market. Further analysis of SEC filings and company data is highly recommended to fully understand its outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is subject to change. It is not financial advice. Conduct thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.spyre.com |
Full time employees 87 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.